Non-GMP manufacturing for liquids and lyophilized drug products

As a specialist in formulation development and analytics, Coriolis completes its offering with the production of non-GMP drug product batches for preclinical and indicative stability studies.

This service includes the manufacturing of liquid and lyophilized products in a large variety of formats and batch sizes as well as scale-up batches and robustness testing or support in technical transfer projects combined with tailored analytical testing.

We offer the supply of preclinical material tailored to your specific drug product, development phase and primary packaging material, and is backed by many years of experience with similar products.

Select your product

Antibody or related product

Peptide

Drug delivery system

Small molecule

High quality standards and biosafety level S1/S2

We provide all our services with the highest quality standards. Each project is carried out by experienced scientists and every report or data presentation is comprehensively checked by a scientific reviewer.

Innovative drugs such as gene- and cell therapy products frequently utilize genetically modified organism or biological substances that fall under biosafety level S1 or S2. If you are working with genetically modified organisms, such as a lentiviral vector, we got you covered. In our manufacturing facilities, we handle liquid and lyophilized drug products up to biosafety level S2.

With dedicated officers for biological and genetical safety, we take care of the biological safety assessment and regulatory paperwork to get project work stated as quickly as possible.